Nasal decongestant sprays and the risk of rebound congestion: MHRA update
Posted 21 Aug 2026
Dr Lisa Devine outlines the MHRA’s 2026 safety advice on the risks of rebound congestion, rhinitis medicamentosa and tachyphylaxis with prolonged use of xylometazoline and oxymetazoline nasal sprays and drops.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.